OBJECTIVETo study the effect of B lymphocyte-induced mature protein-1(Blimp1) expression in bone marrow mononuclear cells on the prognosis of patients with multiple myeloma.

METHODSForty-eight patients with multiple myeloma from January 2014 to January 2015 were selected. The expression of Blimp1 in the bone marrow of all the patients was measured. According to the median score of Blimp1 expression level, the patients was divided into low expression group (L group, 22 cases) and high expression group (H group, 26 cases). The related influencing factors of different Blimp1 expression levels, the clinical efficacy, immunophenotypic changes and progression-free survival(PFS) were compared between different Blimp1 expression groups.

RESULTSThere were no significant differences in sex, age, type, stage and treatment stage between the 2 groups (P> 0.05). The total remission rate of the low expression group was significantly higher than that in the high expression group (P<0.05). However before treatment, there was no significant difference in the positive rate of CD19, CD38, CD56, CD138 and minimal lesion between the 2 groups (P> 0.05); after treatment the positive expression rates of CD38, CD56, CD138 and minimal lesion in the low expression group were significantly lower than those in the high expression group. While the positive expression rate of CD19 was significantly higher than that in high expression group (P<0.05). The PFS of 1, 2 and 3 years in the low expression group was significantly higher than that in the high expression group (P<0.05).

CONCLUSIONThe MM patients with the high in staging and the larger in diffeculty of treatment possess high Blimp1 expression, however, the therapeutic efficacy and prognosis of MM patients with low Blimp1 expression are significantly better than those of MM patients with high Blimp1 expression.